| Name | Title | Contact Details |
|---|
New Century Hospice is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
At Galileo Life, our goal is nothing short of a revolution in the way that healthcare is talked about and delivered. Through the establishment of a dedicated and professional network of Galileo Smart Clinics throughout the country, our vision is the development of a national-level holistic health services and wellness platform specializing in assessment, diagnostic, home-monitoring, and treatment services. The Healthcare Renaissance is here, and Galileo Life Sciences intends to herald the change in Healthcare and re-imagine Healthcare options. Galileo Life Sciences is about the pursuit of alternative solutions both in addition to, and outside of the current Western medical healthcare paradigm. We believe in taking the best of the conventional and combining it with what nature has provided - and what droves of scientific research continues to uncover and confirm - to help us heal, relieve pain, improve sleep, alleviate anxiety, increase appetite, offset the side effects of powerful pharmacological and medical treatments, and much more. Galileo Life Sciences extends an invitation to all practitioners and entrepreneurs in the Healthcare sector, to join us and become part of the bold and rapid global movement to ensure that healthcare is accessible by all in the world.
Ontario Genomics Institute is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
SciFluor Life Sciences is a drug discovery company applying expertise in fluorine chemistry to create a portfolio of differentiated best-in-class therapeutics. The company is creating a portfolio of new chemical entities (NCEs) directed towards precedented biological targets. SciFluor strategically incorporates fluorine or fluorine-containing groups to design drugs with improved pharmacological profiles that provide important benefits over existing therapies such as improved safety, efficacy, more convenient dosing and better patient compliance. This capital-efficient and de-risked drug discovery approach has resulted in the generation of a proprietary pipeline of novel and differentiated small molecule drugs across a range of therapeutic categories and disease areas including retinal disease, CNS disorders, fungal and bacterial infections and inflammatory disease.